2017 FY Results Announcement and Analysts Presentation
Filed with ASX · · 33 pages · English
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $1,337 million for the 12 months ended 30 June 2017. Underlying2 NPAT was up 24% and underlying earnings per share (EPS) grew 26%, both on a constant currency (CC)3 basis. PERFORMANCE HIGHLIGHTS Financial • Revenue $6,923 million o Up 15% at CC3 • Earnings before interest and tax (EBIT) $1,769 million o Underlying
Earlier from CSL
- Appendix 4E, Directors Report and Financial Statements
- CSL Completes Acquisition of Majority Stake in Ruide
- CSL Response to Patent Infringement Complaint
- FDA approves CSL Berhings HAEGARDA
- CSL to Acquire Majority Stake in Chinese Plasma Fractionator
Later from CSL
- CSL Behring Acquires US Biotech Company Calimmune
- FDA Approves Privigen for CIDP Indication
- New Debt Facilities
- CEOs AGM Presentation
- CSL Lifts Profit Guidance
Follow CSL into a list and get an email when it puts out news.
Follow CSL